GH Research (GHRS) Other Operating Expenses (2022 - 2023)
GH Research (GHRS) posted quarterly Other Operating Expenses of -$518000.0 for Q1 2023, down 123.09% year-over-year from $2.2 million in Q1 2022, and down 123.09% quarter-over-quarter from $2.2 million in Q1 2022.
Powered by 
Analysis
GH Research (GHRS) Other Operating Expenses (2022 - 2023) Analysis & Trends
GH Research's Other Operating Expenses history runs 2 years deep, the most recent figure standing at -$518000.0 for Q1 2023.
- In Q1 2023, Other Operating Expenses fell 123.09% year-over-year to -$518000.0; the TTM figure through Dec 2023 stood at -$518000.0 (down 123.09% YoY), while the FY2025 annual figure was $121.1 million, up 20.74% from the prior year.
- Other Operating Expenses for Q1 2023 stood at -$518000.0, down from $2.2 million in the prior quarter.
- The five-year high for Other Operating Expenses was $2.2 million in Q1 2022, with the low at -$518000.0 in Q1 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | GH Research | 1.72 Bn | 1.36 Bn | - |